Valuation: Novavax, Inc.

Market Cap 1.73B 1.53B 1.43B 1.3B 2.46B 166B 2.48B 17.33B 6.72B 84.73B 6.48B 6.34B 272B P/E 2026 *
-16.7x
P/E 2027 * -46.6x
Enterprise Value 1.94B 1.73B 1.61B 1.47B 2.77B 187B 2.8B 19.53B 7.57B 95.48B 7.3B 7.14B 307B EV / Sales 2026 *
5.21x
EV / Sales 2027 * 7.62x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-12.33%+1,148.37% - - 1.75B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-2.32%+23.28%+77.03% 59.26B
+0.89%-0.77%+5.80%+32.89% 47.14B
-0.96%-6.11%+26.70%+31.24% 42.91B
+0.36%+3.39%+350.59%+646.53% 44.13B
-0.20%-0.53%+6.84%+99.07% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+2.33%-8.58%-24.55%+340.08% 23.71B
Average -1.21%-0.64%+53.40%+154.55% 43.6B
Weighted average by Cap. +0.18%-0.40%+58.36%+145.81%

Financials

2026 *2027 *
Net sales 373M 331M 309M 282M 531M 35.92B 536M 3.75B 1.45B 18.31B 1.4B 1.37B 58.86B 266M 237M 221M 201M 379M 25.63B 383M 2.67B 1.04B 13.07B 999M 978M 42.01B
Net income -108M -95.59M -89.1M -81.22M -153M -10.36B -155M -1.08B -419M -5.28B -404M -395M -16.97B -37.93M -33.71M -31.42M -28.64M -54.03M -3.65B -54.55M -381M -148M -1.86B -142M -139M -5.99B
Net Debt 219M 195M 181M 165M 312M 21.09B 315M 2.2B 852M 10.75B 822M 804M 34.56B 303M 270M 251M 229M 432M 29.2B 436M 3.05B 1.18B 14.89B 1.14B 1.11B 47.86B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-